{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-I2R0I4TU/26ca23b9-3e3a-419b-9d83-6d80473420f2/PDF","dcterms:extent":"684 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-I2R0I4TU/9b724846-3c60-484a-882c-5c303f274b62/TEXT","dcterms:extent":"37 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-I2R0I4TU","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2020","dc:creator":["Čebron Lipovec, Nanča","Horvat, Nejc","Janežič, Ana","Jazbar, Janja","Knez, Lea","Kos, Mitja","Locatelli, Igor","Nabergoj Makovec, Urška","Žerovnik, Špela"],"dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:71"},{"@xml:lang":"sl","#text":"str. 85-92"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:4899441","URN:URN:NBN:SI:doc-I2R0I4TU"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"dostop do zdravil"},{"@xml:lang":"sl","#text":"pismenost"},{"@xml:lang":"sl","#text":"pregled zdravil"},{"@xml:lang":"sl","#text":"socialna farmacija"},{"@xml:lang":"sl","#text":"sodelovanje"},{"@xml:lang":"sl","#text":"težave povezane z zdravili"},{"@xml:lang":"sl","#text":"vrednotenje zdravstvenih tehnologij"},{"@xml:lang":"sl","#text":"Zdravila"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Izzivi na poti zdravila od prihoda na trg do varnega in učinkovitega zdravljenja pacienta| Challenges on the medication pathway from market launch to the safe and effective patient treatment|"},"dc:description":[{"@xml:lang":"sl","#text":"Each medication receives marketing authorisation based on its proven safety and effectiveness in clinical trials. However, this is just the start of the path to the effective and safe patient treatment. After obtaining a marketing authorisation, the medication goes through the process of market uptake. The medication price is set, the reimbursement from public funds is determined and potential prescribing restrictions are specified. Once the medication is reimbursed and present on the Slovenian market, it becomes available to patients. However, the treatment instructions are often not understandable to patients. Particularly in chronic diseases, patients show poor adherence in medication therapy. Other medication related problems can also occur, such as side-effects or medication prescribing to different vulnerable populations, e.g. the elderly. Patient-related challenges are addressed and resolved by various pharmacy services, such as medication review and pharmacotherapy review. The path to effective and safe treatment is fraught with challenges, both at the system and patient level. These challenges are the central focus of research in the Chair of Social Pharmacy at the Faculty of Pharmacy, University of Ljubljana"},{"@xml:lang":"sl","#text":"Vsako zdravilo pridobi dovoljenje za promet na podlagi pozitivnega razmerja med koristmi in tveganji, ki izhaja iz kliničnih preskušanj. Vendar pa se s tem pot do učinkovitega in varnega zdravljenja pacienta šele prične. Po pridobitvi dovoljenja za promet se začne postopek umeščanja zdravila v zdravstveni sistem. Zdravilu določimo ceno, višino financiranja iz javnih sredstev in morebitne omejitve predpisovanja. Ko je zdravilo umeščeno in prisotno na slovenskem trgu, postane dostopno pacientom. Pogosto pa pacientom niso razumljiva navodila zdravljenja. Poleg tega pacienti še posebno pri kroničnih boleznih izkazujejo slabo sodelovanja pri zdravljenju z zdravili. Pojavljajo se lahko tudi druge težave, povezane z zdravili, kot npr. neželeni učinki ali predpisovanje zdravila ranljivim populacijam, npr. starostnikom. Težave na ravni pacienta naslavljajo in razrešujejo farmacevtske storitve, kot so pregled uporabe zdravil in farmakoterapijski pregled. Pot zdravila do učinkovitega in varnega zdravljenja je tako polna izzivov, tako na ravni sistema kot pacienta. Na te izzive je osredotočeno raziskovanje Katedre za socialno farmacijo"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-I2R0I4TU","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-I2R0I4TU"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-I2R0I4TU/26ca23b9-3e3a-419b-9d83-6d80473420f2/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-I2R0I4TU/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-I2R0I4TU"}}}}